ClinicalTrials.gg
RecruitingNCT07283367Updated May 1, 2026

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.

A Phase 1/2 interventional study of Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin and Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin in CRC, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
502
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. "Rolling 6" design would be used to conduct dose escalation part of this study. This study consists of phase Ib and phase II. After RP2D was determined in phase Ib, then a phase II study will be conducted to further evaluate the efficacy, safety, tolerability, and PK of the HS-20110 combination therapies in Patients with mCRC.

02

Conditions studied

  • CRC
03

In context

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, aged ≥ 18 years.
  • Participants with confirmed advanced Colorectal Cancer.
  • Participants have at least 1 target lesion other than CNS lesions according to 1.1.
  • MSI was tested to be non-MSI-H, and without BRAF V600E mutation.

Exclusion criteria

Exclusion Criteria:

  • Participants have received or are receiving the following treatment:

    1. Anti-tumor drugs within 14 days prior to the first dose of study treatment; any other IMPs or macromolecular anti-tumor drugs within 28 days prior to the first dose of study treatment.
    2. Local radiotherapy within 2 weeks prior to the first dose of study treatment; irradiation of more than 30% of bone marrow or extensive radiotherapy within 4 weeks prior to the first dose of study treatment.
    3. Major surgery within 4 weeks prior to the first dose of study treatment.
    4. Participants previously treated with drugs that are moderate to strong inhibitors or moderate to strong inducers of cytochrome P450 (CYP) 3A4, strong inhibitors or strong inducers of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) or drugs with a narrow therapeutic range that are sensitive substrates of P-gp or BCRP within 7 days prior to the first dose of the IMP. Participants who need to receive these drugs during the study period should also be excluded.
    5. Current use of drugs known to prolong the or that may cause torsade de pointes. Participants who need to receive these drugs during the study period should also be excluded.
    6. or live-attenuated vaccine within 28 weeks prior to the first dose.
  • Participants who have any Grade ≥ 2 residual toxicity according to (CTCAE, version 5.0) from prior therapies (except alopecia and residual neurotoxicity).
  • Inadequate bone marrow reserve or hepatic and renal functions.
  • Participants with a history of severe allergy (such as anaphylactic shock), previous severe infusion reactions, or allergy to recombinant human or murine proteins.
  • Participants who are allergic to any component of HS-20110 combination therapies.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
502 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Patients in this cohort will receive HS-20110+ Bevacizumab+5-FU/leucovorin in Q2W cycles

    Drug: Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin

  • Experimental
    Cohort 2

    Patients in this cohort will receive HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin in Q2W cycles

    Drug: Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin

  • Experimental
    Cohort 3

    Patients in this cohort will receive HS-20110+Bevacizumab+Oxaliplatin+Capecitabine in Q3W cycles.

    Drug: Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine

Interventions

  • DrugCohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin

    Drug pages: Bevacizumab · Fluorouracil · Leucovorin

    HS-20110 for IV infusion of various dosage in combination with Bevacizumab+5-FU/leucovorin administered in Q2W doseing cycles

  • DrugCohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin

    Drug pages: Bevacizumab · Oxaliplatin · Fluorouracil · Leucovorin

    HS-20110 for IV infusion of various dosage in combination with Bevacizumab+Oxaliplatin+5-FU/leucovorin administered in Q2W doseing cycles

  • DrugCohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine

    Drug pages: Bevacizumab · Oxaliplatin · Capecitabine

    HS-20110 for IV infusion of various dosage in combination with Bevacizumab+Oxaliplatin+Capecitabine administered in Q3W doseing cycles

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) or maximum applicable dose (MAD)

    Time frame: From day 1 to one month after the last dose in Phase 1b

  2. Recommended phase 2 dose (RP2D)

    Time frame: From day 1 to one month after the last dose in Phase 1b

  3. Objective response rate (ORR) as per RECIST v1.1

    Time frame: From day 1 to 3 months after the last patient enrolled in Phase 2

Secondary outcomes

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose modification or permanent discontinuation, and specific laboratory abnormalities

    Time frame: From the first dose until 90 days after the last dose

  2. Objective response rate (ORR)

    Time frame: From first dose until 3 years after last dose

  3. Incidence of anti-HS-20110 antibody (ADA)

    Time frame: From the first dose until 90 days after the last dose

  4. Drug concentrations of the three components of HS-20110 (including antibody-drug conjugates, total antibody, and payload)

    Time frame: From the first dose until 90 days after the last dose

  5. disease control rate (DCR)

    Time frame: From first dose until 3 years after last dose

  6. duration of response (DoR)

    Time frame: From first dose until 3 years after last dose

  7. progression-free survival (PFS)

    Time frame: From first dose until 3 years after last dose

  8. overall survival (OS)

    Time frame: From first dose until 3 years after last dose

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2029, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 15, 2025
StartActual
Dec 22, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07283367
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Dec 22, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 1, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Fluorouracil · Leucovorin · Oxaliplatin · Capecitabine

Start the discussion